Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Related Citations for PubMed (Select 24625557)

1.

Δ9-THC exposure attenuates aversive effects and reveals appetitive effects of K2/'Spice' constituent JWH-018 in mice.

Hyatt WS, Fantegrossi WE.

Behav Pharmacol. 2014 Jun;25(3):253-7. doi: 10.1097/FBP.0000000000000034.

PMID:
24625557
2.

Cannabinoids in disguise: Δ9-tetrahydrocannabinol-like effects of tetramethylcyclopropyl ketone indoles.

Wiley JL, Marusich JA, Lefever TW, Grabenauer M, Moore KN, Thomas BF.

Neuropharmacology. 2013 Dec;75:145-54. doi: 10.1016/j.neuropharm.2013.07.022. Epub 2013 Aug 2.

3.

JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.

Ginsburg BC, Schulze DR, Hruba L, McMahon LR.

J Pharmacol Exp Ther. 2012 Jan;340(1):37-45. doi: 10.1124/jpet.111.187757. Epub 2011 Sep 30.

4.

Differential drug-drug interactions of the synthetic Cannabinoids JWH-018 and JWH-073: implications for drug abuse liability and pain therapy.

Brents LK, Zimmerman SM, Saffell AR, Prather PL, Fantegrossi WE.

J Pharmacol Exp Ther. 2013 Sep;346(3):350-61. doi: 10.1124/jpet.113.206003. Epub 2013 Jun 25.

5.

Dependence Potential of the Synthetic Cannabinoids JWH-073, JWH-081, and JWH-210: In Vivo and In Vitro Approaches.

Cha HJ, Lee KW, Song MJ, Hyeon YJ, Hwang JY, Jang CG, Ahn JI, Jeon SH, Kim HU, Kim YH, Seong WK, Kang H, Yoo HS, Jeong HS.

Biomol Ther (Seoul). 2014 Jul;22(4):363-9. doi: 10.4062/biomolther.2014.039.

6.

Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity.

Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL.

PLoS One. 2011;6(7):e21917. doi: 10.1371/journal.pone.0021917. Epub 2011 Jul 6.

7.

Apparent inverse relationship between cannabinoid agonist efficacy and tolerance/cross-tolerance produced by Δ⁹-tetrahydrocannabinol treatment in rhesus monkeys.

Hruba L, Ginsburg BC, McMahon LR.

J Pharmacol Exp Ther. 2012 Sep;342(3):843-9. doi: 10.1124/jpet.112.196444. Epub 2012 Jun 20.

8.

Delta9-tetrahydrocannabinol decreases somatic and motivational manifestations of nicotine withdrawal in mice.

Balerio GN, Aso E, Berrendero F, Murtra P, Maldonado R.

Eur J Neurosci. 2004 Nov;20(10):2737-48.

PMID:
15548217
9.

Cannabinoid receptors and reward in the rat: a conditioned place preference study.

Cheer JF, Kendall DA, Marsden CA.

Psychopharmacology (Berl). 2000 Jul;151(1):25-30.

PMID:
10958113
10.

Endogenous cannabinoids as an aversive or counter-rewarding system in the rat.

Sañudo-Peña MC, Tsou K, Delay ER, Hohman AG, Force M, Walker JM.

Neurosci Lett. 1997 Feb 21;223(2):125-8.

PMID:
9089689
12.

Tolerance to the reinforcing effects of morphine in delta9-tetrahydrocannabinol treated mice.

Jardinaud F, Roques BP, Noble F.

Behav Brain Res. 2006 Oct 16;173(2):255-61. Epub 2006 Aug 1.

PMID:
16884789
13.

Δ9-Tetrahydrocannabinol-like discriminative stimulus effects of compounds commonly found in K2/Spice.

Gatch MB, Forster MJ.

Behav Pharmacol. 2014 Dec;25(8):750-7. doi: 10.1097/FBP.0000000000000093.

PMID:
25325289
14.

1-Pentyl-3-phenylacetylindoles and JWH-018 share in vivo cannabinoid profiles in mice.

Wiley JL, Marusich JA, Martin BR, Huffman JW.

Drug Alcohol Depend. 2012 Jun 1;123(1-3):148-53. doi: 10.1016/j.drugalcdep.2011.11.001. Epub 2011 Nov 27.

15.
16.
17.

Inhalation exposure to smoke from synthetic "marijuana" produces potent cannabimimetic effects in mice.

Wiebelhaus JM, Poklis JL, Poklis A, Vann RE, Lichtman AH, Wise LE.

Drug Alcohol Depend. 2012 Dec 1;126(3):316-23. doi: 10.1016/j.drugalcdep.2012.05.034. Epub 2012 Jul 7.

18.

Differential anxiogenic, aversive, and locomotor effects of THC in adolescent and adult rats.

Schramm-Sapyta NL, Cha YM, Chaudhry S, Wilson WA, Swartzwelder HS, Kuhn CM.

Psychopharmacology (Berl). 2007 May;191(4):867-77. Epub 2007 Jan 9.

PMID:
17211649
19.

Human metabolites of synthetic cannabinoids JWH-018 and JWH-073 bind with high affinity and act as potent agonists at cannabinoid type-2 receptors.

Rajasekaran M, Brents LK, Franks LN, Moran JH, Prather PL.

Toxicol Appl Pharmacol. 2013 Jun 1;269(2):100-8. doi: 10.1016/j.taap.2013.03.012. Epub 2013 Mar 26.

20.

Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ(9)-THC: mechanism underlying greater toxicity?

Fantegrossi WE, Moran JH, Radominska-Pandya A, Prather PL.

Life Sci. 2014 Feb 27;97(1):45-54. doi: 10.1016/j.lfs.2013.09.017. Epub 2013 Sep 29. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk